# A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

> **NCT07435311** · PHASE1 · COMPLETED · sponsor: **R-Pharm** · enrollment: 118 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** RPH-002
- **DRUG:** Erbitux®
- **DRUG:** cisplatin
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT07435311
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-15
- **Primary completion:** 2024-07-17
- **Final completion:** 2024-07-17
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07435311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07435311, "A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07435311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*